vancomycin + piperacillin-tazobactam

Vancomycin + piperacillin-tazobactam is a combination of two intravenous antibiotics frequently used in hospitals for the empiric treatment of severe infections, especially in critically ill or septic patients. Vancomycin is a glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala termini of cell wall precursor units, primarily targeting Gram-positive organisms including methicillin-resistant Staphylococcus aureus (MRSA). Piperacillin is an extended-spectrum ureidopenicillin that also inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), and tazobactam is a β-lactamase inhibitor that extends the spectrum of piperacillin against β-lactamase-producing bacteria. The combination provides broad-spectrum coverage against Gram-positive, Gram-negative, and anaerobic pathogens. However, multiple meta-analyses have shown this regimen carries an increased risk for acute kidney injury compared to other anti-pseudomonal beta-lactams combined with vancomycin[1][2][3]. The mechanism behind this nephrotoxicity remains debated.

Brand names

Zosyn

Other names

vanc-zosynvosyn